Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl.

@article{Maguire2016InteractionsBC,
  title={Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl.},
  author={David R. Maguire and Charles P. France},
  journal={European journal of pharmacology},
  year={2016},
  volume={784},
  pages={
          199-206
        }
}
View on PubMed
europepmc.org
15 Citations
Background Citations
8
Methods Citations
1

Tables from this paper

15 Citations

Effects of the cannabinoid CB1-receptor neutral antagonist AM4113 and antagonist/inverse agonist rimonabant on fentanyl discrimination in male rats.

Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed‐dose ratio

Effects of Opioid/Cannabinoid Mixtures on Impulsivity and Memory in Rhesus Monkeys

Evidence is provided supporting the notion that opioid/cannabinoid mixtures that are effective for treating pain do not have greater, and in some cases have less, adverse effects compared with larger doses of each drug alone.

Interactions between opioids and cannabinoids: Economic demand for opioid/cannabinoid mixtures.

Effects of morphine/CP55940 mixtures on an impulsive choice task in rhesus monkeys

The results extend previous work showing that cannabinoids enhance antinociceptive effects but not adverse (reinforcing) effects of opioids, and the effects of morphine/CP5540 mixtures on cognitive performance need to be assessed during and after daily drug administration.

Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys

Because MCAM selectively attenuates opioid self-administration for prolonged periods, this novel drug could be a safe and effective alternative to currently available treatments for opioid abuse.

The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain

Preclinical and clinical evidence of various endocannabinoid system targets as potential therapeutic strategies for inflammatory and neuropathic pain conditions are examined.

Cannabinoids for Pain Management

Given the numerous nuances of products and the ECS dosing for pain, both acute and chronic, dosing should be done in an escalating manner, so that the therapeutic benefit is appreciated.

Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset.

The findings of this review confirm the importance of prompt and reliable information available for health professionals and more specific analytic techniques and designed preventive strategies are required to face unprecedented SC challenge.

Identification of novel phytocannabinoids from Ganoderma by label-free dynamic mass redistribution assay.

References

SHOWING 1-10 OF 46 REFERENCES

Impact of Efficacy at the μ-Opioid Receptor on Antinociceptive Effects of Combinations of μ-Opioid Receptor Agonists and Cannabinoid Receptor Agonists

Cannabinoids increase the antinociceptive potency of higher efficacy opioid receptor agonists more than lower efficacy agonists; however, because much smaller doses of each drug can be administered in combinations while achieving adequate pain relief and that other effects of opioids do not appear to be enhanced by cannabinoids, these results provide additional support for combining opioids with cannabinoids to treat pain.

Interactions between Δ9-tetrahydrocannabinol and μ opioid receptor agonists in rhesus monkeys: discrimination and antinociception

Investigating interactions between the discriminative stimulus and antinociceptive effects of μ opioid receptor agonists and Δ9-tetrahydrocannabinol (THC) in rhesus monkeys suggests that attenuation of morphine by THC can result from perceptual masking rather than common pharmacodynamic mechanisms or pharmacokinetic interactions.

Interactions between μ-Opioid Receptor Agonists and Cannabinoid Receptor Agonists in Rhesus Monkeys: Antinociception, Drug Discrimination, and Drug Self-Administration

Cannabinoid receptor agonist CP 55,940 and WIN 55,212 enhanced the antinociceptive effects but not the discriminative stimulus or positive reinforcing effects of μ-opioid receptor agonists in rhesus monkeys, supporting the view that combining cannabinoid and opioid receptor agonism might result in enhanced treatment effectiveness for pain without similarly enhancing abuse and dependence liability.

Synergistic interactions between cannabinoid and opioid analgesics.

Cannabinoid-opioid interactions during neuropathic pain and analgesia.

Effects of Direct- and Indirect-Acting Serotonin Receptor Agonists on the Antinociceptive and Discriminative Stimulus Effects of Morphine in Rhesus Monkeys

5-HT receptor agonists increase the potency of morphine in an assay of antinociception, even under conditions where 5-HT agonists are themselves without effect, without increasing (and in some cases decreasing) the potencyof morphine in a drug discrimination assay.

Characterization of Cannabinoid Agonists and Apparent pA2 Analysis of Cannabinoid Antagonists in Rhesus Monkeys Discriminating Δ9-Tetrahydrocannabinol

  • L. McMahon
  • Biology, Chemistry
    Journal of Pharmacology and Experimental Therapeutics
  • 2006
The results demonstrate that the discrim inative stimulus effects of Δ9-THC are selective for cannabinoid activity, and the results of Schild analysis suggest that the same receptors mediate the discriminative stimulus results of Δ 9-THc, CP 55940, and WIN 55212-2.

The µ opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the μ opioid receptor

The strategy of irreversible antagonism can be used effectively to differentiate opioids with varying degrees of intrinsic efficacy at the µ opioid receptors in a pigeon drug discrimination procedure, and the short-acting effect of βFNA in the pigeon suggests that the recovery of µ opioid receptor function varies across species.

Interactions between &Dgr;9-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys

It is indicated that THC does not significantly enhance the positive reinforcing effects of heroin, further supporting the view that combining cannabinoid and opioid receptor agonists (e.g. for treating pain) does not increase, and might decrease, the abuse liability of individual drugs.

Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys.